PATENT CLAIM ANALYSIS

Application Number: 16307362
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-07
Patent Classification: ["514", "252160"]

Abstract:
The present invention relates to the fused pyrimidine piperidine cyclic derivative represented by the following formula (I) and a pharmaceutically acceptable salt thereof and a process for preparing the same, wherein R1, R2, R3, R4, R5, X, Y and Z are defined as in the description. The present invention further provides use of said fused pyrimidine piperidine cyclic derivative in manufacture of a medicament for preventing or treating FGFR kinase mediated disease such as cancer.

Claim (Index 18):
The method according to  claim 17 , wherein said cancer is selected from the group consisting of multiple myeloma, myeloproliferative disease, endometrial cancer, prostate cancer, bladder cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, colorectal cancer, oral squamous cell carcinoma, squamous cell carcinoma, liver cancer, kidney cancer, colon cancer and non-small cell lung cancer.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.43333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15047892', '14511326', '13394525', '14132653', '14402198']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7920163556950118
- 35 USC 102 Novelty (BERT): 0.5294256149572019
- Combined Prediction Score: 0.7657572816212308
- Mean Citation Score: 331.866862
- Max Citation Score: 336.3714
- Similarity Product: 236.845683208251

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test